AVITA (RCEL) said late Thursday the US Food and Drug Administration granted 510(k) clearance for the Cohealyx collagen-based dermal matrix, expanding the company's capabilities in the treatment of full-thickness wounds.
The company said it co-developed the product with Regenity Biosciences.
AVITA said it intends to develop clinical data for Cohealyx early next year and expects to launch full commercialization efforts in the US at the start of Q2.
"We also anticipate Cohealyx will generate significant revenue as we penetrate the full-thickness skin defect market," the company said.
AVITA shares were up 2.3% in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。